Advertisement

Online combination algorithm for non-invasive assessment of chronic hepatitis B related liver fibrosis and cirrhosis in resource-limited settings

      Highlights

      • We evaluated six free noninvasive markers for chronic hepatitis B related fibrosis.
      • Algorithm based on four scores and their corresponding thresholds was created.
      • An online version of algorithm is available on www.chb-lfc.com.
      • Algorithm is an applicable and accurate tool for diagnosis of CHB related fibrosis and cirrhosis.

      Abstract

      Objective

      The use of commercially available noninvasive markers for chronic hepatitis B (CHB) related fibrosis is not widely available in developing countries so clinicians in those countries frequently use free alternatives. We aimed to create an optimized algorithm for selection of patients with the highest probability for presence/absence of significant liver fibrosis and cirrhosis based on the use of multiple free scores.

      Methods

      We evaluated six free noninvasive markers for CHB related fibrosis against liver biopsy and selected the best thresholds for prediction/exclusion of significant fibrosis and cirrhosis in CHB patients. Algorithm based on four scores and their corresponding thresholds was created.

      Results

      The calculator based on developed algorithm can be found at http://www.chb-lfc.com. We evaluated 211 patients in main group and 65 patients in external validation group. We selected four scores for creation of combination algorithm. The algorithm was able to classify 123/211 (58.3%) patients with a 93.5% accuracy of correct classification for prediction of presence/absence of significant fibrosis in main group. In validation group, the algorithm was able to classify 48/65 (73.8%) of patients with 93.8% (45/48) overall accuracy. When used to predict presence/absence of cirrhosis, the algorithm was able to correctly classify 181/211 (85.8%) and 59/65 (90.8%) of patients in main and validation group, respectively, with an overall accuracy of 97.8% and 98.3%, respectively.

      Conclusion

      Developed algorithm based on routine laboratory tests is a usable, applicable and accurate tool for diagnosis of CHB related fibrosis and cirrhosis, suitable for resource-limited settings where more expensive modalities are unavailable.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • World Health Organization
        Hepatitis B: fact sheet No 204.
        ([cited 2014]; Available from:)
        • Sebastiani G.
        • Alberti A.
        Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.
        World J Gastroenterol. 2006; 12: 3682-3694
        • Brunetti E.
        • Silini E.
        • Pistorio A.
        • Cavallero A.
        • Marangio A.
        • Bruno R.
        • et al.
        Coarse vs. fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis.
        J Hepatol. 2004; 40: 501-506
        • Cadranel J.F.
        • Rufat P.
        • Degos F.
        Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).
        Hepatology. 2000; 32: 477-481
        • Colloredo G.
        • Guido M.
        • Sonzogni A.
        • Leandro G.
        Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease.
        J Hepatol. 2003; 39: 239-244
        • Rousselet M.C.
        • Michalak S.
        • Dupre F.
        • Croue A.
        • Bedossa P.
        • Saint-Andre J.P.
        • et al.
        Sources of variability in histological scoring of chronic viral hepatitis.
        Hepatology. 2005; 41: 257-264
        • Terjung B.
        • Lemnitzer I.
        • Dumoulin F.L.
        • Effenberger W.
        • Brackmann H.H.
        • Sauerbruch T.
        • et al.
        Bleeding complications after percutaneous liver biopsy. An analysis of risk factors.
        Digestion. 2003; 67: 138-145
        • West J.
        • Card T.R.
        Reduced mortality rates following elective percutaneous liver biopsies.
        Gastroenterology. 2010; 139: 1230-1237
        • Regev A.
        • Berho M.
        • Jeffers L.J.
        • Milikowski C.
        • Molina E.G.
        • Pyrsopoulos N.T.
        • et al.
        Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection.
        Am J Gastroenterol. 2002; 97: 2614-2618
        • Bedossa P.
        • Dargere D.
        • Paradis V.
        Sampling variability of liver fibrosis in chronic hepatitis C.
        Hepatology. 2003; 38: 1449-1457
        • Castéra L.
        Noninvasive methods to assess liver disease in patients with hepatitis B or C.
        YGAST. 2012; 142: 1293-1302.e4
        • Pinzani M.
        • Vizzutti F.
        • Arena U.
        • Marra F.
        Technology insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography.
        Nat Clin Pract Gastroenterol Hepatol. 2008; 5: 95-106
        • Chon Y.E.
        • Choi E.H.
        • Song K.J.
        • Park J.Y.
        • Kim do Y.
        • Han K.H.
        • et al.
        Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis.
        PLoS One. 2012; 7: e44930
        • Friedrich-Rust M.
        • Ong M.F.
        • Martens S.
        • Sarrazin C.
        • Bojunga J.
        • Zeuzem S.
        • et al.
        Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.
        Gastroenterology. 2008; 134: 960-974
        • Poynard T.
        • Ngo Y.
        • Munteanu M.
        • Thabut D.
        • Ratziu V.
        Noninvasive markers of hepatic fibrosis in chronic hepatitis B.
        Curr Hepat Rep. 2011; 10: 87-97
        • Mallet V.
        • Dhalluin-Venier V.
        • Roussin C.
        • Bourliere M.
        • Pettinelli M.E.
        • Giry C.
        • et al.
        The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.
        Aliment Pharmacol Ther. 2009; 29: 409-415
        • European Association for the Study of the Liver
        EASL clinical practice guidelines: management of chronic hepatitis B virus infection.
        J Hepatol. 2012; 57: 167-185
        • Bossuyt P.M.
        • Reitsma J.B.
        • Bruns D.E.
        • Gatsonis C.A.
        • Glasziou P.P.
        • Irwig L.M.
        • et al.
        The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.
        Ann Intern Med. 2003; 138: W1-W12
        • Forns X.
        • Ampurdanes S.
        • Llovet J.M.
        • Aponte J.
        • Quinto L.
        • Martinez-Bauer E.
        • et al.
        Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.
        Hepatology. 2002; 36: 986-992
        • Hui A.Y.
        • Chan H.L.
        • Wong V.W.
        • Liew C.T.
        • Chim A.M.
        • Chan F.K.
        • et al.
        Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model.
        Am J Gastroenterol. 2005; 100: 616-623
        • Islam S.
        • Antonsson L.
        • Westin J.
        • Lagging M.
        Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers.
        Scand J Gastroenterol. 2005; 40: 867-872
        • Lok A.S.
        • Ghany M.G.
        • Goodman Z.D.
        • Wright E.C.
        • Everson G.T.
        • Sterling R.K.
        • et al.
        Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.
        Hepatology. 2005; 42: 282-292
        • Sterling R.K.
        • Lissen E.
        • Clumeck N.
        • Sola R.
        • Correa M.C.
        • Montaner J.
        • et al.
        Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
        Hepatology. 2006; 43: 1317-1325
        • Wai C.T.
        • Greenson J.K.
        • Fontana R.J.
        • Kalbfleisch J.D.
        • Marrero J.A.
        • Conjeevaram H.S.
        • et al.
        A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.
        Hepatology. 2003; 38: 518-526
        • The French METAVIR Cooperative Study Group
        Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C.
        Hepatology. 1994; 20: 15-20
        • Poynard T.
        • Halfon P.
        • Castéra L.
        • Munteanu M.
        • Imbert-Bismut F.
        • Ratziu V.
        • et al.
        Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages.
        Clin Chem. 2007; 53: 1615-1622
        • Castera L.
        • Sebastiani G.
        • Le Bail B.
        • de Ledinghen V.
        • Couzigou P.
        • Alberti A.
        Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.
        J Hepatol. 2010; 52: 191-198
        • Maimone S.
        • Calvaruso V.
        • Pleguezuelo M.
        • Squadrito G.
        • Amaddeo G.
        • Jacobs M.
        • et al.
        An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers.
        J Viral Hepat. 2009; 16: 769-774
        • Castéra L.
        • Pinzani M.
        Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?.
        Gut. 2010; 59: 861-866
        • Mehta S.H.
        • Lau B.
        • Afdhal N.H.
        • Thomas D.L.
        Exceeding the limits of liver histology markers.
        J Hepatol. 2009; 50: 36-41
        • Bissell D.M.
        Assessing fibrosis without a liver biopsy: are we there yet?.
        Gastroenterology. 2004; 127: 1847-1849
        • Rockey D.C.
        • Bissell D.M.
        Noninvasive measures of liver fibrosis.
        Hepatology. 2006; 43: S113-S120
        • Vigano M.
        • Paggi S.
        • Lampertico P.
        • Fraquelli M.
        • Massironi S.
        • Ronchi G.
        • et al.
        Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation.
        Aliment Pharmacol Ther. 2011; 34: 353-362
        • Ott J.J.
        • Stevens G.A.
        • Groeger J.
        • Wiersma S.T.
        Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity.
        Vaccine. 2012; 30: 2212-2219
        • Lemoine M.
        • Thursz M.
        • Njie R.
        • Dusheiko G.
        Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action.
        Liver Int. 2014; 34: 12-15
        • Salkic N.N.
        • Jovanovic P.
        • Hauser G.
        • Brcic M.
        FibroTest/fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.
        Am J Gastroenterol. 2014; 109: 796-809